CD133, a stem cell marker, in neuroblastoma

doi:10.3969/j.issn.2095-4344.2015.50.010

Abstract

Abstract:

BACKGROUND: Neuroblastoma is the most common solid tumor in infants and children. Targeting cancer stem cell therapy can be expected to cure cancer radically, but because of small number, anti-apoptotic and anti-chemotherapy capacity, cancer stem cells are not sensitive to the radiotherapy and chemotherapy.
OBJECTIVE: To explore the expression of stem cell marker CD133 in neuroblastoma and its clinical significance.
METHODS: Fifty-eight children with neuroblastoma admitted at Department of Pediatric Surgery, the First Affiliated Hospital of Xinjiang Medical University, China from June 2004 to February 2014 were enrolled, including 46 cases of neuroblastoma and 12 cases of ganglion neuroblastoma. Then, the expression level of CD133 was analyzed by immunohistochemistry method, and the relationship between pathological types, International Neuroblastoma Staging System stage, survival time after surgery and the expression level of CD133 was explored.
RESULTS AND CONCLUSION: There were 22 cases (48%) of neuroblastoma positive for CD133, and 4 cases (33%) of ganglion neuroblastoma positive for CD133. CD133 mainly expressed in the tumor cell cytoplasm. The expression rates of CD133 in different clinical stages were significantly different (P=0.011), which were 21% for stages 1 and 2, 64% for stages 3 and 4, 36% for stage 4S. And the positive rates of CD133 between patients with good prognosis and patients with poor prognosis were significantly different (P=0.031), which were 29% and 57%, respectively. The life cycle of CD133-negative patients was significantly longer than that of CD133-positive infants
(P < 0.05). There were tightly connections between CD133 and the occurrence, development, and prognosis of neuroblastoma, and thus, CD133 is of great significance to assess the survival time after surgery and improve of the diagnosis and treatment of neuroblastoma.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

CLC Number:

R394.2

Fan Jia-rong, Li Wan-fu, Liang Ting . CD133, a stem cell marker, in neuroblastoma[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(50): 8090-8094.

Figures/Tables 4

References

[1] Chen X,Zhu YJ,Han LL,et al.Chemokine receptor 4 gene silencing blocks neuroblastoma metastasis in vitro. Neural Regen Res. 2014;9(10): 1063-1067.

[2] Kushner BH, Modak S, Kramer K, et al. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer. 2014;120(13):2050-2059.

[3] Hashimoto K, Aoyagi K, Isobe T, et al. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer. 2014; 17(1):97-106.

[4] Meany HJ, London WB, Ambros PF, et al. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61(11):1932-1939.

[5] Minter MR, Zhang M, Ates RC, et al. Type-1 interferons contribute to oxygen glucose deprivation induced neuro-inflammation in BE(2)M17 human neuroblastoma cells. J Neuroinflammation. 2014;11:43.

[6] Tirino V, Desiderio V, Paino F, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013;27(1):13-24.

[7] Williams SA, Anderson WC, Santaguida MT, et al. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest. 2013;93(9):970-982.

[8] Meany HJ, London WB, Ambros PF, et al. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61(11):1932-1939.

[9] Zhang D, Sun B, Zhao X, et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer. 2014;13:207.

[10] Chen L, Chang WC, Hung YC, et al. Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line. Reprod Sci. 2014;21(3):386-394.

[11] Oktem G, Bilir A, Uslu R, et al. Expression profiling of stem cell signaling alters with spheroid formation in CD133high/ CD44high prostate cancer stem cells. Oncol Lett. 2014;7(6): 2103-2109.

[12] Shin JH, Lee YS, Hong YK, et al. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. J Neurooncol. 2013;115(3):333-341.

[13] Braekeveldt N, Wigerup C, Gisselsson D, et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer. 2015;136(5):E252-261.

[14] Albanus RD, Juliani Siqueira Dalmolin R, Alves Castro MA, et al. Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression. PLoS One. 2013;8(12):e82457.

[15] Rihani A, Van Maerken T, De Wilde B, et al. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. Pediatr Blood Cancer. 2014;61(10):1867-1870.

[16] Mai HM, Zheng JW, Wang YA, et al. CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma. Chin Med J (Engl). 2013;126(1):88-94.

[17] El-Khattouti A, Selimovic D, Haïkel Y, et al. Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response. Cancer Lett. 2014;343(1):123-133.

[18] Van Craenenbroeck EM, Van Craenenbroeck AH, van Ierssel S, et al. Quantification of circulating CD34+/KDR+/CD45dim endothelial progenitor cells: analytical considerations. Int J Cardiol. 2013;167(5):1688-1695.

[19] 曲利园,王亚东,王贵齐,等.国内外大肠癌筛查现状分析及对我国大肠癌筛查的建议[J].中国全科医学,2007,10(19):1584-1586.

[20] Hou Y, Zou Q, Ge R, et al. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012;22(1):259-272.

[21] Kim HM, Haraguchi N, Ishii H, et al. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon.Ann Surg Oncol. 2012;19 Suppl 3:S539-548.

[22] Sukowati CH, Anfuso B, Torre G, et al. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS One. 2013;8(10):e76830.

[23] Michishita M, Ezaki S, Ogihara K, et al. Identification of tumor-initiating cells in a canine hepatocellular carcinoma cell line. Res Vet Sci. 2014;96(2):315-322.

[24] Yamashita T, Honda M, Nakamoto Y, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 2013;57(4): 1484-1497.

[25] Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12): 1749-1758.

[26] Piao LS, Hur W, Kim TK, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012;315(2):129-137.

[27] Salnikov AV, Kusumawidjaja G, Rausch V, et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 2009;275(2):185-193.

[28] Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J. 2006; 20(8):1045-1054.

[29] Dan YY, Riehle KJ, Lazaro C, et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages.Proc Natl Acad Sci U S A. 2006;103(26):9912-9917.

[30] Ishizawa K, Rasheed ZA, Karisch R, et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell. 2010; 7(3):279-282.